Abstract
Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy.
Copyright © 2021 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Cell Cycle / drug effects
-
Cell Cycle / physiology
-
Cyclin D / genetics
-
Cyclin D / metabolism
-
Cyclin E / genetics
-
Cyclin E / metabolism
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 4 / metabolism
-
Cyclin-Dependent Kinase 6 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 6 / metabolism
-
Humans
-
Mice
-
Molecular Targeted Therapy / methods
-
Neoplasms / drug therapy*
-
Neoplasms / pathology*
Substances
-
Antineoplastic Agents
-
Cyclin D
-
Cyclin E
-
CDK4 protein, human
-
CDK6 protein, human
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase 6